Infliximab Limits Injury in Myocardial Infarction.
Christopher LiviaSara S InglisRuben Crespo-DiazSkylar RizzoRyan MahlbergMonique S BagwellMatthew HillestadSatsuki YamadaDhivya Vadhana Meenakshi SiddharthanRaman Deep SinghXing LiD Kent ArrellPaul StalboergerTyra WittAbdallah El SabbaghMunveer RihalCharanjit S RihalAndre TerzicJozef BartunekAtta BehfarPublished in: Journal of the American Heart Association (2024)
Profiling of coronary thrombus aspirates in patients with ST-segment-elevation MI revealed highest association for tumor necrosis factor-α in injury risk. Infliximab-mediated immune modulation offers an actionable pathway to alter MI-induced inflammatory response, preserving contractility and limiting adverse structural remodeling.